---
title: "Ascendis Pharma A/S (ASND.US) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ASND.US/overview.md"
symbol: "ASND.US"
name: "Ascendis Pharma A/S"
parent: "https://longbridge.com/en/quote/ASND.US.md"
datetime: "2026-04-15T16:05:15.073Z"
locales:
  - [en](https://longbridge.com/en/quote/ASND.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ASND.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ASND.US/overview.md)
---

# Ascendis Pharma A/S (ASND.US) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Address | Tuborg Boulevard 12, Hellerup, Capital Region of Denmark, Denmark |
| Website | [ascendispharma.com](https://ascendispharma.com) |

## Company Profile

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

## Key Executives

| Name | Title |
|------|-------|
| Jan Moller Mikkelsen | President, CEO, Member of Executive Board & Executive Director |
| Albert Cha | Independent Chairman |
| Scott T. Smith | CFO, Executive VP & Member of Executive Board |
| Pedersen Anni Lotte Kirstine Sonderbjerg | Executive VP, Chief Administrative Officer & Member of the Executive Board |
| Michael Wolff Jensen | Executive VP, Chief Legal Officer & Member of the Executive Board |
| Mads Bodenhoff | Senior VP, Head of Finance & Principal Accounting Officer |
| Lars Holtug | Independent Director |
| Lisa Bright Morrison | Independent Director |
| Siham Imani | Independent Director |

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| RA Capital Management, L.P. | 16.64% | 2025-12-31 |
| Westfield Capital Management Company, L.P. | 8.39% | 2025-12-31 |
| Avoro Capital Advisors LLC | 8.27% | 2025-12-31 |
| FMR LLC | 6.72% | 2025-12-31 |
| Janus Henderson Group plc | 6.57% | 2025-12-31 |
| T. Rowe Price Group, Inc. | 5.24% | 2025-12-31 |
| Artisan Partners Limited Partnership | 5.22% | 2025-12-31 |
| Capital Research and Management Company | 5.05% | 2025-12-31 |
| Massachusetts Financial Services Company | 3.05% | 2025-12-31 |
| Wellington Management Group LLP | 2.85% | 2025-12-31 |

## Business Breakdown

| Segment | Revenue | Ratio |
|---------|---------|-------|
| Biotechnology | 720132000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Ascendis Pharma A/S Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Biotechnology",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## Geographic Segments

| Region | Revenue | Ratio |
|--------|---------|-------|
| United States of America (USA) | 546388000 | 75.87% |
| Europe (excludes Denmark) | 108046000 | 15% |
| Rest of World | 52798000 | 7.33% |
| Denmark | 12900000 | 1.79% |


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**